TMSB10

Summary

TMSB10 (thymosin beta 10, HGNC:11879) is a protein-coding gene on chromosome 2p11.2, encoding Thymosin beta-10 (P63313). Plays an important role in the organization of the cytoskeleton. It is a selective cancer dependency (DepMap: 30.5% of cell lines).

Predicted to enable actin monomer binding activity. Predicted to be involved in regulation of cell migration. Predicted to be located in cytoskeleton. Predicted to be active in cytoplasm.

Source: NCBI Gene 9168 — RefSeq curated summary.

At a glance

• Druggable target: yes
• Cancer dependency (DepMap): dependent in 30.5% of screened cell lines
• MANE Select transcript: NM_021103

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11879
Approved symbol	TMSB10
Name	thymosin beta 10
Location	2p11.2
Locus type	gene with protein product
Status	Approved
Aliases	TB10
Ensembl gene	ENSG00000034510
Ensembl biotype	protein_coding
OMIM	188399
Entrez	9168

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 9 protein_coding

ENST00000233143, ENST00000877287, ENST00000877288, ENST00000877289, ENST00000929522, ENST00000929523, ENST00000929524, ENST00000929525, ENST00000929526

RefSeq mRNA: 1 — MANE Select: NM_021103 NM_021103

CCDS: CCDS1970

Canonical transcript exons

ENST00000233143 — 3 exons

Exon	Start	End
ENSE00000767123	84906003	84906117
ENSE00000799789	84906389	84906671
ENSE00001004473	84905656	84905718

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.98.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2400.9340 / max 59942.2474, expressed in 1828 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21185	2389.6393	1828
21187	9.2241	1593
21186	1.8826	964
21188	0.1881	61

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.98	gold quality
monocyte	CL:0000576	99.96	gold quality
leukocyte	CL:0000738	99.96	gold quality
mononuclear cell	CL:0000842	99.96	gold quality
mucosa of transverse colon	UBERON:0004991	99.96	gold quality
granulocyte	CL:0000094	99.95	gold quality
ganglionic eminence	UBERON:0004023	99.95	gold quality
stromal cell of endometrium	CL:0002255	99.94	gold quality
right lung	UBERON:0002167	99.94	gold quality
upper lobe of left lung	UBERON:0008952	99.93	gold quality
colonic mucosa	UBERON:0000317	99.92	gold quality
rectum	UBERON:0001052	99.92	gold quality
tibial nerve	UBERON:0001323	99.92	gold quality
gall bladder	UBERON:0002110	99.92	gold quality
calcaneal tendon	UBERON:0003701	99.92	gold quality
corpus epididymis	UBERON:0004359	99.92	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.92	gold quality
periodontal ligament	UBERON:0008266	99.92	gold quality
upper lobe of lung	UBERON:0008948	99.92	gold quality
ileal mucosa	UBERON:0000331	99.91	gold quality
smooth muscle tissue	UBERON:0001135	99.90	gold quality
vermiform appendix	UBERON:0001154	99.90	gold quality
decidua	UBERON:0002450	99.90	gold quality
caecum	UBERON:0001153	99.89	gold quality
peritoneum	UBERON:0002358	99.89	gold quality
right testis	UBERON:0004534	99.89	gold quality
adipose tissue of abdominal region	UBERON:0007808	99.89	gold quality
omental fat pad	UBERON:0010414	99.89	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.89	gold quality
lymph node	UBERON:0000029	99.88	gold quality

Single-cell (SCXA)

Detected in 82 experiment(s), a significant marker in 33.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	18583.11
E-CURD-46	yes	15566.96
E-MTAB-10042	yes	11735.01
E-MTAB-10287	yes	11202.50
E-CURD-122	yes	11033.62
E-MTAB-8142	yes	10398.68
E-MTAB-11121	yes	10371.30
E-MTAB-7316	yes	10166.83
E-GEOD-134144	yes	9603.23
E-GEOD-130148	yes	9012.85
E-GEOD-124263	yes	8110.45
E-CURD-98	yes	7764.70
E-ANND-2	yes	7760.82
E-HCAD-9	yes	7724.56
E-HCAD-31	yes	4395.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RARA

miRNA regulators (miRDB)

19 targeting TMSB10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12121	99.99	66.64	255
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-5090	93.28	60.86	94
HSA-MIR-6775-5P	92.43	61.00	132
HSA-MIR-6774-3P	89.14	65.20	68

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 30.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 27)

• TB10 plays a critical role in the regulation of anchorage-independent growth and assembly of actin filaments. (PMID:12481941)
• Introduction of E-Tmod cDNA into a tumor cell line reverses TB10 mediated apoptosis and restored actin architectures. (PMID:14741341)
• TB10 has a role in progression of human thyroid carcinomas, particularly in the anaplastic histotypes (PMID:15254683)
• Inhibition of Ras signal transduction by thymosin beta(10) results in antiangiogenic and antitumor effects, suggesting that thymosin beta(10) may be valuable in anticancer therapy. (PMID:15665289)
• results strongly suggest that Thr20 is specifically required for actin sequestration by TB10 in ovarian cancer cells (PMID:16012174)
• the distribution of staining for thymosin beta10 was inverse of staining for F-actin. These data support a physiological role for thymosin beta10 in sequestration of G-actin as well as in cancer cell motility. (PMID:16786322)
• Expression of TB10 and its role in non-small cell lung cancer are reported. (PMID:18789485)
• Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation. (PMID:19194824)
• outlines for the first time that salivary glands during foetal life express and secrete peptides such as beta-thymosins probably involved in the development of the oral cavity and its annexes (PMID:19337364)
• The expression of Tbeta10 in the human kidney during the initial phases of its physiological development, mainly restricted in the proximal and the distal tubuli. (PMID:20836742)
• Describe beta-thymosins in bronchoalveolar lavage fluid and their possible involvement in the pathogenesis of scleroderma lung disease. (PMID:21314931)
• The results show, for the first time, a strong expression of thymosin beta 10 in the human salivary glands during the initial phases of the physiological development, present at the 13th week of gestation, and suggesting a role for the peptide in the salivary glands’ organogenesis. (PMID:21733645)
• hypomethylation of the promoter is not associated with its overexpression in non-small cell lung cancer (PMID:22038593)
• Amplification of thymosin beta 10 is associated with metastatic and aggressive papillary thyroid carcinomas. (PMID:22161024)
• Thymosin beta10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production. (PMID:22623951)
• Low expression of Tbeta10 is associated with metastatic phenotype of CCA in vitro and in vivo. (PMID:24053380)
• Regarding HCC, Tbeta4 reactivity was detected in 7/23 cases (30%) and Tbeta10 reactivity in 22/23 (97%) cases analyzed, adding HCC to human cancers that express these beta-thymosins. (PMID:24704991)
• Tbeta10 human recombinant proteins promoted the expression of VEGF-C by activating AKT phosphorylation in lung cancer cell lines. (PMID:24854554)
• High expression levels of TMSB10 correlated with lymphatic metasttases in papillary thyroid carcinoma, especially in the central neck region. (PMID:24974154)
• High expression of thymosin beta 10 is associated with hepatocellular carcinoma. (PMID:25037578)
• TMSB10 may hold promise as a minimally invasive serum cancer biomarker for the diagnosis of breast cancer and a potential therapeutic target which will facilitate the development of a novel therapeutic strategy against breast cancer. (PMID:28179017)
• Findings show high thymosin beta 10 (TMSB10) expression was remarkably associated with the advanced tumor stage, large tumor size, distant metastasis, and poor prognosis, and acted as an independent factor for predicting poor overall survival in hepatocellular carcinoma (HCC) patients. (PMID:30787051)
• TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma. (PMID:32319572)
• Thymosin beta10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. (PMID:33349268)
• PTEN/AKT upregulation of TMSB10 contributes to lung cancer cell growth and predicts poor survival of the patients. (PMID:33686397)
• TMSB10 Promotes Progression of Clear Cell Renal Cell Carcinoma via JUN Transcription Regulation. (PMID:35414502)
• The Clinical Relevance and Functional Implications of Thymosin Beta-10 in Glioma. (PMID:38026448)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tmsb10b	ENSMUSG00000091955
rattus_norvegicus		ENSRNOG00000067030

Protein

Protein identifiers

Thymosin beta-10 — P63313 (reviewed: P63313)

All UniProt accessions (1): P63313

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in the organization of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization.

Subcellular location. Cytoplasm. Cytoskeleton.

Similarity. Belongs to the thymosin beta family.

RefSeq proteins (1): NP_066926* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001152	Beta-thymosin	Family
IPR038386	Beta-thymosin_sf	Homologous_superfamily

Pfam: PF01290

UniProt features (15 total): modified residue 9, compositionally biased region 2, initiator methionine 1, chain 1, sequence variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P63313-F1	73.22	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 23, 34, 39, 41, 2, 4, 12, 15, 21

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 203 (showing top): RNGTGGGC_UNKNOWN, MYAATNNNNNNNGGC_UNKNOWN, YAGI_AML_WITH_INV_16_TRANSLOCATION, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, HSIAO_HOUSEKEEPING_GENES, TATTATA_MIR374, GCM_PSME1, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, WOO_LIVER_CANCER_RECURRENCE_UP, JIANG_TIP30_TARGETS_UP, GOBP_ACTIN_FILAMENT_ORGANIZATION, YANAGISAWA_LUNG_CANCER_RECURRENCE, LIAO_METASTASIS, SCHLOSSER_SERUM_RESPONSE_DN, WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_DN

GO Biological Process (2): actin filament organization (GO:0007015), regulation of cell migration (GO:0030334)

GO Molecular Function (4): actin monomer binding (GO:0003785), protein sequestering activity (GO:0140311), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (2): cytoskeleton (GO:0005856), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
actin cytoskeleton organization	1
supramolecular fiber organization	1
cell migration	1
regulation of cell motility	1
actin binding	1
protein binding	1
molecular sequestering activity	1
cytoskeletal protein binding	1
binding	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

48 interactions, top by confidence:

A	B	Type	Score
NCOA4	FTL	psi-mi:“MI:0914”(association)	0.790
TMSB10	ALAS1	psi-mi:“MI:0915”(physical association)	0.720
ALAS1	TMSB10	psi-mi:“MI:0915”(physical association)	0.720
VPS45	STX16	psi-mi:“MI:0914”(association)	0.620
KRTAP9-2	TMSB10	psi-mi:“MI:0915”(physical association)	0.560
TMSB10	KRTAP9-2	psi-mi:“MI:0915”(physical association)	0.560
GRB2	ARHGEF35	psi-mi:“MI:0914”(association)	0.530
TMSB10	POT1	psi-mi:“MI:0915”(physical association)	0.510
TMSB10	TERF1	psi-mi:“MI:0915”(physical association)	0.370
TMSB10	TERF2	psi-mi:“MI:0915”(physical association)	0.370
TMSB10	TERF2IP	psi-mi:“MI:0915”(physical association)	0.370
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
BCAR1	PSMD11	psi-mi:“MI:0914”(association)	0.350
BCAR1	MYO1C	psi-mi:“MI:0914”(association)	0.350
SH3GL3	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
CSK	LCK	psi-mi:“MI:0914”(association)	0.350
CAV1	PPM1G	psi-mi:“MI:0914”(association)	0.350
PEBP1	PRPSAP2	psi-mi:“MI:0914”(association)	0.350
SRC	ACTN4	psi-mi:“MI:0914”(association)	0.350
HTRA4	PSMD12	psi-mi:“MI:0914”(association)	0.350
PRKD2	ACOT7	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
ACTB	ENAH	psi-mi:“MI:0914”(association)	0.350
GSTP1	TMSB10	psi-mi:“MI:0914”(association)	0.350

BioGRID (76): TMSB10 (Two-hybrid), KRTAP9-2 (Two-hybrid), TMSB10 (Affinity Capture-MS), LGALS3 (Co-fractionation), PFN1 (Co-fractionation), TMSB10 (Biochemical Activity), TMSB10 (Proximity Label-MS), TMSB10 (Proximity Label-MS), TMSB10 (Two-hybrid), TMSB10 (Two-hybrid), TMSB10 (Affinity Capture-MS), TMSB10 (Affinity Capture-MS), TMSB10 (Affinity Capture-MS), TMSB10 (Affinity Capture-MS), TMSB10 (Affinity Capture-MS)

ESM2 similar proteins: A0MD36, A2VEA7, A3KMT2, A3KMU5, O21950, O56774, O74416, P04972, P0C766, P10430, P13636, P18545, P26352, P35940, P40023, P44588, P51397, P53329, P54827, P61248, P63312, P63313, P63314, P68191, P68192, P68193, P90335, Q02651, Q04558, Q0P641, Q0THU0, Q1RBT8, Q28CI6, Q320R9, Q3Z1M3, Q54UN8, Q57Y88, Q5E969, Q5R853, Q69560

Diamond homologs: O14604, P0CG34, P0CG35, P0DX04, P18758, P20065, P21752, P21753, P26351, P26352, P33248, P34032, P62326, P62327, P62328, P62329, P63312, P63313, P63314, Q5R7H8, Q6S9C5, Q6ZWY8, Q7YRC3, Q8T697, Q95274, Q9DET5, Q9DFJ9, Q9I954, Q9I955, Q9I980, Q9W7M8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 58 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by BRAF and RAF1 fusions	5	18.1×	5e-04
Meiotic synapsis	5	15.0×	9e-04
Platelet activation, signaling and aggregation	5	11.2×	2e-03
Signaling by Receptor Tyrosine Kinases	6	6.6×	5e-03
Hemostasis	7	5.4×	5e-03
Infectious disease	8	4.2×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
epidermal growth factor receptor signaling pathway	5	24.3×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

239 predictions. Top by Δscore:

Variant	Effect	Δscore
2:84906113:AGAGA:A	donor_gain	1.0000
2:84906114:GAGA:G	donor_gain	1.0000
2:84906114:GAGAG:G	donor_gain	1.0000
2:84906116:GA:G	donor_gain	1.0000
2:84906118:G:GG	donor_gain	1.0000
2:84906002:GGATT:G	acceptor_gain	0.9900
2:84906115:A:T	donor_gain	0.9900
2:84906115:AGA:A	donor_gain	0.9900
2:84906115:AGAGT:A	donor_loss	0.9900
2:84906116:GAG:G	donor_gain	0.9900
2:84906116:GAGTG:G	donor_loss	0.9900
2:84906117:AGTG:A	donor_loss	0.9900
2:84906118:GTGA:G	donor_loss	0.9900
2:84906119:T:G	donor_loss	0.9900
2:84905716:ACGG:A	donor_loss	0.9800
2:84905717:CGGT:C	donor_loss	0.9800
2:84905718:GGT:G	donor_loss	0.9800
2:84905719:G:GG	donor_gain	0.9800
2:84905719:G:T	donor_loss	0.9800
2:84905720:TGAG:T	donor_loss	0.9800
2:84905721:GAGT:G	donor_loss	0.9800
2:84906120:G:GC	donor_loss	0.9800
2:84906121:AGTG:A	donor_loss	0.9800
2:84906388:GCC:G	acceptor_gain	0.9800
2:84905714:GCACG:G	donor_gain	0.9700
2:84906387:A:AG	acceptor_gain	0.9600
2:84906388:G:GG	acceptor_gain	0.9600
2:84906388:GCCAT:G	acceptor_gain	0.9600
2:84905722:AGTG:A	donor_loss	0.9500
2:84906122:G:C	donor_loss	0.9500

AlphaMissense

292 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:84906054:T:C	F13L	0.963
2:84906056:C:A	F13L	0.963
2:84906056:C:G	F13L	0.963
2:84906105:C:T	P30S	0.945
2:84906106:C:A	P30Q	0.936
2:84906070:T:C	L18P	0.935
2:84906095:G:C	K26N	0.924
2:84906095:G:T	K26N	0.924
2:84906117:A:C	T34P	0.918
2:84906105:C:A	P30T	0.912
2:84906103:T:A	L29Q	0.905
2:84906106:C:G	P30R	0.898
2:84906398:A:C	Q37P	0.885
2:84906103:T:C	L29P	0.869
2:84906392:T:A	I35N	0.865
2:84906070:T:A	L18Q	0.858
2:84906093:A:G	K26E	0.856
2:84906401:A:T	E38V	0.849
2:84906046:T:A	I10N	0.844
2:84906055:T:C	F13S	0.844
2:84906402:G:C	E38D	0.842
2:84906402:G:T	E38D	0.842
2:84906094:A:C	K26T	0.839
2:84906094:A:T	K26M	0.829
2:84906109:C:T	T31I	0.826
2:84906098:C:A	N27K	0.825
2:84906098:C:G	N27K	0.825
2:84906105:C:G	P30A	0.823
2:84906092:G:C	E25D	0.816
2:84906092:G:T	E25D	0.816

dbSNP variants (sampled 300 via entrez): RS1000954437 (2:84905058 C>T), RS1001028099 (2:84905340 G>A), RS1001561956 (2:84904471 T>C), RS1001846706 (2:84904438 A>C,G), RS1001908104 (2:84905788 C>G,T), RS1002849202 (2:84904135 A>T), RS1003560588 (2:84906946 G>C), RS1003999743 (2:84906604 C>A), RS1004852032 (2:84905366 C>G), RS1005187605 (2:84903864 T>C), RS1005735474 (2:84904173 C>G), RS1006773498 (2:84905268 C>A,G), RS1007153543 (2:84905522 C>CG), RS1008531017 (2:84906535 C>T), RS1008601590 (2:84906902 T>C)

Disease associations

OMIM: gene MIM:188399 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067186 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7148	TMSB10		0.00	0

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.38	Kd	41.48	nM	CHEMBL5653589
7.19	ED50	64.23	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149621: Binding affinity to human TMSB10 incubated for 45 mins by Kinobead based pull down assay	kd	0.0415	uM

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	3
sodium arsenite	increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Benzo(a)pyrene	increases expression	2
Tretinoin	increases expression	2
Valproic Acid	affects cotreatment, increases expression, decreases expression, increases methylation	2
Cyclosporine	increases expression	2
Particulate Matter	decreases expression, increases abundance	2
dicrotophos	decreases expression	1
methyleugenol	increases expression	1
alpha phellandrene	increases expression	1
glycidyl methacrylate	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
methylparaben	increases expression	1
nickel sulfate	increases expression	1
raltitrexed	increases expression	1
CD 437	decreases expression	1
chloropicrin	increases expression	1
K 7174	increases expression	1
3-(4’-hydroxy-3’-adamantylbiphenyl-4-yl)acrylic acid	decreases expression	1
jinfukang	increases expression	1
(+)-JQ1 compound	decreases expression	1
Oxaliplatin	increases expression	1
Zoledronic Acid	decreases expression	1
Acetaminophen	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	increases expression	1
Diazinon	increases methylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652663	Binding	Binding affinity to human TMSB10 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1E9	Abcam HCT 116 TMSB10 KO	Cancer cell line	Male
CVCL_B3JR	Abcam HEK293T TMSB10 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.